Guardant Health, Inc. $GH Stock Holdings Trimmed by Swiss National Bank

Swiss National Bank lessened its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 11.4% in the second quarter, HoldingsChannel reports. The fund owned 212,100 shares of the company’s stock after selling 27,200 shares during the period. Swiss National Bank’s holdings in Guardant Health were worth $11,038,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Main Management ETF Advisors LLC raised its stake in shares of Guardant Health by 1.7% during the second quarter. Main Management ETF Advisors LLC now owns 21,257 shares of the company’s stock valued at $1,106,000 after purchasing an additional 348 shares in the last quarter. Ensign Peak Advisors Inc increased its stake in Guardant Health by 4.8% during the 2nd quarter. Ensign Peak Advisors Inc now owns 43,425 shares of the company’s stock valued at $2,260,000 after buying an additional 1,975 shares during the period. TD Waterhouse Canada Inc. raised its position in shares of Guardant Health by 64.1% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 4,740 shares of the company’s stock worth $240,000 after buying an additional 1,851 shares in the last quarter. Primecap Management Co. CA lifted its stake in shares of Guardant Health by 51.1% in the 2nd quarter. Primecap Management Co. CA now owns 65,990 shares of the company’s stock worth $3,434,000 after acquiring an additional 22,304 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH lifted its stake in shares of Guardant Health by 25.0% in the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 195,186 shares of the company’s stock worth $10,157,000 after acquiring an additional 39,038 shares during the period. Institutional investors own 92.60% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on GH shares. Citigroup boosted their target price on Guardant Health from $65.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. BTIG Research boosted their price objective on Guardant Health from $80.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Mizuho set a $100.00 price objective on Guardant Health in a report on Thursday, October 30th. JPMorgan Chase & Co. lifted their target price on Guardant Health from $60.00 to $70.00 and gave the stock an “overweight” rating in a report on Thursday, September 25th. Finally, UBS Group boosted their price target on shares of Guardant Health from $80.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Twenty-three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $77.14.

Guardant Health Stock Up 0.3%

Shares of NASDAQ GH opened at $108.13 on Friday. The stock’s fifty day simple moving average is $80.11 and its 200 day simple moving average is $60.85. The stock has a market capitalization of $13.63 billion, a price-to-earnings ratio of -33.68 and a beta of 1.56. Guardant Health, Inc. has a 52-week low of $29.91 and a 52-week high of $112.43.

Guardant Health (NASDAQ:GH) last announced its earnings results on Wednesday, October 29th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.09. Guardant Health’s quarterly revenue was up 38.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.88) EPS. Guardant Health has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Helmy Eltoukhy sold 300,000 shares of Guardant Health stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $59.45, for a total value of $17,835,000.00. Following the transaction, the chief executive officer directly owned 2,123,499 shares of the company’s stock, valued at $126,242,015.55. This trade represents a 12.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Medina Manuel Hidalgo sold 2,165 shares of the business’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $54.16, for a total transaction of $117,256.40. Following the sale, the director owned 851 shares in the company, valued at $46,090.16. This represents a 71.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 313,161 shares of company stock worth $18,996,062 over the last ninety days. 6.10% of the stock is currently owned by company insiders.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.